Kenneth Brian Gordon, MD

Publications

• Meaningful Change Thresholds for the Psoriasis Symptoms and Signs Diary: A Secondary Analysis of a Randomized Clinical Trial.

  (Papp KA, Gordon K, Strober B, Zhuo J, Becker B, Zhong Y, Beaumont JL, Pham TP, Kisa R, Napoli AA, Banerjee S, Armstrong AW.) JAMA Dermatol. 2024 Feb 01;160(2):204-209 PMID: 38117487 PMCID: PMC10733845 SCOPUS ID: 2-s2.0-85180996904 12/20/2023

• Efficacy and safety of subcutaneous spesolimab for the prevention of generalised pustular psoriasis flares (Effisayil 2): an international, multicentre, randomised, placebo-controlled trial.

  (Morita A, Strober B, Burden AD, Choon SE, Anadkat MJ, Marrakchi S, Tsai TF, Gordon KB, Thaçi D, Zheng M, Hu N, Haeufel T, Thoma C, Lebwohl MG.) Lancet. 2023 Oct 28;402(10412):1541-1551 PMID: 37738999 SCOPUS ID: 2-s2.0-85173148730 09/23/2023

• Treatment of plaque psoriasis with deucravacitinib (POETYK PSO-2 study): a plain language summary.

  (Strober B, Thaçi D, Sofen H, Kircik L, Gordon KB, Foley P, Rich P, Paul C, Bagel J, Colston E, Throup J, Kundu S, Sekaran C, Linaberry M, Banerjee S, Papp KA.) Immunotherapy. 2023 Aug;15(11):787-797 PMID: 37150956 SCOPUS ID: 2-s2.0-85161651265 05/08/2023

• Next Generation PDE4 Inhibitors that Selectively Target PDE4B/D Subtypes: A Narrative Review

  (Blauvelt A, Langley RG, Gordon KB, Silverberg JI, Eyerich K, Sommer MOA, Felding J, Warren RB.) Dermatology and Therapy. December 2023;13(12):3031-3042 SCOPUS ID: 2-s2.0-85175655223 12/01/2023

• Methotrexate for inflammatory skin disease in pediatric patients: Consensus treatment guidelines.

  (Siegfried EC, Arkin LM, Chiu YE, Hebert AA, Callen JP, Castelo-Soccio L, Co DO, Cordoro KM, Curran ML, Dalrymple AM, Flohr C, Gordon KB, Hanna D, Irvine AD, Kim S, Kirkorian AY, Lara-Corrales I, Lindstrom J, Paller AS, Reyes M, Begolka WS, Tom WL, Van Voorhees AS, Vleugels RA, Lee LW, Davies OMT, Brandling-Bennett HA.) Pediatr Dermatol. 2023;40(5):789-808 PMID: 37316462 SCOPUS ID: 2-s2.0-85161815440 06/15/2023

• Differentiating biologics to prevent psoriatic arthritis in patients with psoriasis – Authors' reply

  (Singla S, Putman M, Liew J, Gordon K.) The Lancet Rheumatology. June 2023;5(6):e313 SCOPUS ID: 2-s2.0-85159612732 06/01/2023

• Association between biological immunotherapy for psoriasis and time to incident inflammatory arthritis: a retrospective cohort study

  (Singla S, Putman M, Liew J, Gordon K.) The Lancet Rheumatology. April 2023;5(4):e200-e207 SCOPUS ID: 2-s2.0-85150252036 04/01/2023

• Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: Efficacy and safety results from the 52-week, randomized, double-blinded, phase 3 Program fOr Evaluation of TYK2 inhibitor psoriasis second trial.

  (Strober B, Thaçi D, Sofen H, Kircik L, Gordon KB, Foley P, Rich P, Paul C, Bagel J, Colston E, Throup J, Kundu S, Sekaran C, Linaberry M, Banerjee S, Papp KA.) J Am Acad Dermatol. 2023 Jan;88(1):40-51 PMID: 36115523 SCOPUS ID: 2-s2.0-85144040320 09/18/2022

• Anti-IL 23 biologics for the treatment of plaque psoriasis.

  (Vu A, Ulschmid C, Gordon KB.) Expert Opin Biol Ther. 2022 Dec;22(12):1489-1502 PMID: 36243011 SCOPUS ID: 2-s2.0-85140999891 10/16/2022

• Super-response to guselkumab treatment in patients with moderate-to-severe psoriasis: age, body weight, baseline Psoriasis Area and Severity Index, and baseline Investigator's Global Assessment scores predict complete skin clearance.

  (Reich K, Gordon KB, Strober B, Langley RG, Miller M, Yang YW, Shen YK, You Y, Zhu Y, Foley P, Blauvelt A.) J Eur Acad Dermatol Venereol. 2022 Dec;36(12):2393-2400 PMID: 35920762 SCOPUS ID: 2-s2.0-85136531215 08/04/2022

• Deucravacitinib in moderate-to-severe psoriasis.

  (Vu A, Maloney V, Gordon KB.) Immunotherapy. 2022 Nov;14(16):1279-1290 PMID: 36373503 SCOPUS ID: 2-s2.0-85142918537 11/15/2022

• Bimekizumab Safety in Patients With Moderate to Severe Plaque Psoriasis: Pooled Results From Phase 2 and Phase 3 Randomized Clinical Trials.

  (Gordon KB, Langley RG, Warren RB, Okubo Y, Stein Gold L, Merola JF, Peterson L, Wixted K, Cross N, Deherder D, Thaçi D.) JAMA Dermatol. 2022 Jul 01;158(7):735-744 PMID: 35544084 PMCID: PMC9096693 SCOPUS ID: 2-s2.0-85130365798 05/12/2022